Injectable Poly-L-Lactic Acid (Sculptra): Technical Considerations in Soft-Tissue Contouring

Abstract

The authors therefore have opted for a more conservative approach in their treatment recommendations. Higher volume dilution (8 to 12 cc), fewer vials used at each session, injections placed in the subcutaneous plane without any product being placed in the dermis, adequate time between injection sessions (at least 6 weeks), and postinjection patient massage should decrease the risks and avoid the potential complications associated with poly-L-lactic acid soft-tissue augmentation.

Injectable poly-L-lactic acid for cosmetic enhancement: Learning from the European experience

“…As physicians have become more familiar with injectable PLLA, it has become apparent that the reconstitution and administration of this injectable device (injectable filler), including correct placement of the material, are important parameters in ensuring optimal outcomes and minimizing adverse events. 14 This article aims to review the literature regarding the use of injectable PLLA in the European Union and United States for both HIV-associated facial lipoatrophy and facial cosmetic augmentation, in addition to describing how previous experience with PLLA can help improve future treatment outcomes. The information reported in this article is as detailed within the reviewed references and, as such, may not reflect manufacturer recommendations for the preparation and administration of injectable PLLA.…”

Silicon-associated subcutaneous lesion presenting as a mass: a confounding histopathologic correlation

“…It has been also suggested that toxic substances already present in the body are attracted to the site of implant and initiate a granulomatous reaction [19]. This theory may explain why granulomas may develop throughout the bed of implantation rather than being limited to a few foci [18].…”

Optimizing Injectable Poly-L-Lactic Acid Administration for Soft Tissue Augmentation: The Rationale for Three Treatment Sessions

“…Because each patient responds differently to treatment with injectable PLLA, it is important to allow sufficient time between treatments to avoid overcorrection of the original deficit. Overcorrection of the injected area may produce an unwanted visual effect, and may contribute to the formation of subcutaneous nodules (31,53,54). It should be emphasized that the effects of treatment with injectable PLLA are gradual and long lasting (55).…”